drugset
drugset / Trial / NCT03321890

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03321890 ↗

Phase 2 Unknown 102 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory PTCL.

Timeline

Start
2017-03-07
Primary completion
2020-12-01
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral
Background Cyclophosphamide Other / unclassified 50 mg Oral
Background Etoposide Small molecule 50 mg Oral
Background Methotrexate Small molecule 10 mg Oral
Background Prednisone Other / unclassified 20 mg Oral

Indications

peripheral T-cell lymphoma, not otherwise specified